Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2010 2
2011 3
2012 6
2013 5
2014 5
2015 6
2016 7
2017 4
2018 6
2019 3
2020 1
2021 4
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Taliglucerase Alfa.
[No authors listed] [No authors listed] 2021 May 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 May 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000979 Free Books & Documents. Review.
Taliglucerase alfa is a biosynthetic synthetic enzyme closely related to beta-glucocerebrosidase, which is a normal component of human milk. ...
Taliglucerase alfa is a biosynthetic synthetic enzyme closely related to beta-glucocerebrosidase, which is a normal component …
Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
Zimran A, Wajnrajch M, Hernandez B, Pastores GM. Zimran A, et al. Orphanet J Rare Dis. 2018 Feb 23;13(1):36. doi: 10.1186/s13023-018-0776-8. Orphanet J Rare Dis. 2018. PMID: 29471850 Free PMC article. Review.
Here, we review the findings across six key taliglucerase alfa clinical studies. A total of 33 treatment-naive adult patients were randomized to taliglucerase alfa 30 U/kg or 60 U/kg in a 9-month, multicentre, randomized, double-blind, parallel-group, …
Here, we review the findings across six key taliglucerase alfa clinical studies. A total of 33 treatment-naive adult patients …
Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
Grabowski GA, Golembo M, Shaaltiel Y. Grabowski GA, et al. Mol Genet Metab. 2014 May;112(1):1-8. doi: 10.1016/j.ymgme.2014.02.011. Epub 2014 Mar 2. Mol Genet Metab. 2014. PMID: 24630271 Review.
Such modifications add to production costs. Taliglucerase alfa is a plant cell-expressed acid beta-glucosidase approved in the United States and other countries for ERT in adults with GD1. A plant-based expression system, using carrot root cell cultures, was develop …
Such modifications add to production costs. Taliglucerase alfa is a plant cell-expressed acid beta-glucosidase approved in the …
Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease.
Gupta P, Pastores GM. Gupta P, et al. Pediatric Health Med Ther. 2017 Jun 16;8:73-81. doi: 10.2147/PHMT.S93634. eCollection 2017. Pediatric Health Med Ther. 2017. PMID: 29388611 Free PMC article. Review.
These steps are critical to the success of ERT for the treatment of visceral and hematologic manifestations of GD. Taliglucerase alfa is the first US Food and Drug Administration-approved plant-cell-expressed recombinant human protein, using carrot root cell culture …
These steps are critical to the success of ERT for the treatment of visceral and hematologic manifestations of GD. Taliglucerase a …
Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
Cravo R, Rotman V, Oliveira PMN, Defendi HGT, Conceição DA, Xavier JR, Chertkoff R, Noronha TG, Maia MLS. Cravo R, et al. Blood Cells Mol Dis. 2018 Feb;68:160-162. doi: 10.1016/j.bcmd.2017.01.005. Epub 2017 Jan 16. Blood Cells Mol Dis. 2018. PMID: 28131618
We evaluated retrospectively, efficacy and safety of taliglucerase alfa for Gaucher disease in a Brazilian population. Thirteen patients were included for efficacy analysis only one of them naive to enzyme replacement therapy. ...Only three patients (out of 35) had …
We evaluated retrospectively, efficacy and safety of taliglucerase alfa for Gaucher disease in a Brazilian population. Thirtee …
Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
Titievsky L, Schuster T, Wang R, Younus M, Palladino A, Quazi K, Wajnrajch MP, Hernandez B, Becker PS, Weinreb NJ, Chambers C, Mansfield R, Taylor L, Tseng LJ, Kaplan P. Titievsky L, et al. Orphanet J Rare Dis. 2022 Apr 1;17(1):145. doi: 10.1186/s13023-022-02289-7. Orphanet J Rare Dis. 2022. PMID: 35365177 Free PMC article.
BACKGROUND: Limited real-world data from routine clinical care are available on the safety and effectiveness of treatment with taliglucerase alfa in patients with Gaucher disease (GD). METHODS: Taliglucerase Alfa Surveillance (TALIAS), a multinational …
BACKGROUND: Limited real-world data from routine clinical care are available on the safety and effectiveness of treatment with taliglucer …
Alglucerase.
[No authors listed] [No authors listed] 2024 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000749 Free Books & Documents. Review.
Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naive or previously treated with imiglucerase.
Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R. Zimran A, et al. Blood Cells Mol Dis. 2018 Feb;68:163-172. doi: 10.1016/j.bcmd.2016.10.005. Epub 2016 Oct 20. Blood Cells Mol Dis. 2018. PMID: 27839981 Free article. Clinical Trial.
Taliglucerase alfa is an enzyme replacement therapy approved for treatment of Gaucher disease (GD) in children and adults in several countries. ...These findings extend the taliglucerase alfa safety and efficacy profile and demonstrate long-term clinic …
Taliglucerase alfa is an enzyme replacement therapy approved for treatment of Gaucher disease (GD) in children and adults in s …
Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Kuter DJ, Wajnrajch M, Hernandez B, Wang R, Chertkoff R, Zimran A. Kuter DJ, et al. Blood Cells Mol Dis. 2020 May;82:102418. doi: 10.1016/j.bcmd.2020.102418. Epub 2020 Feb 24. Blood Cells Mol Dis. 2020. PMID: 32146279 Clinical Trial.
A multicenter, open-label, expanded-access study followed the safety of taliglucerase alfa, a plant cell-expressed recombinant enzyme replacement therapy (ERT), in adults with Gaucher disease previously treated with imiglucerase. ...Fifty-eight patients received …
A multicenter, open-label, expanded-access study followed the safety of taliglucerase alfa, a plant cell-expressed recombinant …
Taliglucerase alfa approved for Gaucher disease.
Traynor K. Traynor K. Am J Health Syst Pharm. 2012 Jun 15;69(12):1009. doi: 10.2146/news120041. Am J Health Syst Pharm. 2012. PMID: 22644968 No abstract available.
54 results